Anthony Coles - McKesson Independent Director
| MCK Stock | USD 527.32 2.49 0.47% |
Director
Dr. N. Anthony Coles, Jr. M.D. is an Independent Director of the Company. Dr. Coles, age 58, has served as Chairman and Chief Executive Officer of Yumanity Therapeutics, LLC, a company focused on transforming drug discovery for neurodegenerative diseases, since October 2014. From October 2013 to October 2014, Dr. Coles served as Chairman and CEO of TRATE Enterprises LLC, a privately held company. Dr. Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from 2012 until 2013, having served as its President, Chief Executive Officer and a member of its board of directors from 2008 until 2012. Prior to joining Onyx Pharmaceuticals, Inc. in 2008, he was President, Chief Executive Officer and a member of the board of directors of NPS Pharmaceuticals, Inc., a public biopharmaceutical company. Before joining NPS Pharmaceuticals, Inc. in 2005, he served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck Co., Inc., BristolMyers Squibb Company and Vertex Pharmaceuticals Incorporated. Dr. Coles currently serves as a director of Regeneron Pharmaceuticals, Inc. In addition to having previously served as a director of Onyx Pharmaceuticals, Inc. and NPS Pharmaceuticals, Inc., he was formerly a director of Laboratory Corporation of America Holdings, Campus Crest Communities, Inc. and CRISPR Therapeutics. Dr. Coles was a director of the Company since April 2014. since 2014.
| Age | 57 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | 6555 State Highway 161, Irving, TX, United States, 75039 |
| Phone | 972 446 4800 |
| Web | https://www.mckesson.com |
McKesson Management Efficiency
The company has Return on Asset of 0.0363 % which means that on every $100 spent on assets, it made $0.0363 of profit. This is way below average. McKesson's management efficiency ratios could be used to measure how well McKesson manages its routine affairs as well as how well it operates its assets and liabilities. At this time, McKesson's Return On Tangible Assets are quite stable compared to the past year. Return On Capital Employed is expected to rise to 0.29 this year, although the value of Return On Assets will most likely fall to 0.03. Total Current Liabilities is expected to rise to about 57.9 B this year. Liabilities And Stockholders Equity is expected to rise to about 75.3 B this yearSimilar Executives
| Showing other executives | DIRECTOR Age | ||
| Robrecht Michiels | EDAP TMS SA | N/A | |
| Lawrence Bacow | Henry Schein | 65 | |
| Jody Feragen | Patterson Companies | 62 | |
| Paul Brons | Henry Schein | 76 | |
| Norman Matthews | Henry Schein | 82 | |
| James Wiltz | Patterson Companies | 71 | |
| Truitt Allcott | Owens Minor | N/A | |
| Sarena Lin | Patterson Companies | 45 | |
| David Simmons | Owens Minor | 51 | |
| John Gerdelman | Owens Minor | 64 | |
| Patricia Hall | Cardinal Health | 67 | |
| Clayton Jones | Cardinal Health | 67 | |
| Ellen Rudnick | Patterson Companies | 67 | |
| James Rogers | Owens Minor | 70 | |
| Robert Frenzel | Patterson Companies | 46 | |
| John Buck | Patterson Companies | 66 | |
| Carrie Cox | Cardinal Health | 62 | |
| Gerald Benjamin | Henry Schein | 64 | |
| Kurt Kuehn | Henry Schein | 63 | |
| Barry Alperin | Henry Schein | 77 | |
| Mark McGettrick | Owens Minor | 63 | |
Management Performance
| Return On Asset | 0.0363 |
McKesson Leadership Team
Elected by the shareholders, the McKesson's board of directors comprises two types of representatives: McKesson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of McKesson. The board's role is to monitor McKesson's management team and ensure that shareholders' interests are well served. McKesson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, McKesson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bansi Nagji, Executive Vice President - Corporate Strategy and Business Development | ||
| Andrew Bryant, Independent Director | ||
| W Dunbar, Independent Director | ||
| LeAnn Smith, Executive Officer | ||
| Kenneth Washington, Independent Director | ||
| M Jacobs, Independent Director | ||
| Edward Mueller, Independent Chairman of the Board | ||
| Marie Knowles, Independent Director | ||
| N Coles, Independent Director | ||
| Linda Mantia, Independent Director | ||
| Nancy Flores, Executive Vice President, Chief Technology Officer, Chief Information Officer | ||
| Tracy Faber, Chief Human Resource Officer, Executive Vice President | ||
| Susan Salka, Independent Director | ||
| Donald Knauss, Independent Director | ||
| Alton Irby, Independent Director | ||
| Maria Martinez, Independent Director | ||
| Brad Lerman, Independent Director | ||
| Kathleen Thompson, Director | ||
| Michele Lau, Executive Officer | ||
| Jorge Figueredo, Executive Vice President - Human Resources | ||
| Napoleon Rutledge, Senior Vice President Chief Accounting Officer, Controller | ||
| James Beer, CFO and Executive VP | ||
| Wayne Budd, Independent Director | ||
| Lori JD, Board Advisor | ||
| Dominic Caruso, Independent Director | ||
| Lori Schechter, Executive Vice President Chief Compliance Officer, General Counsel | ||
| Sundeep Reddy, Senior Vice President Principal Accounting Officer, Corporate Controller | ||
| Mary Jacobs, Independent Director | ||
| Holly Weiss, VP Relations | ||
| Pete Slone, Senior Affairs | ||
| John Hammergren, Chairman, CEO and Pres | ||
| Bradley Lerman, Independent Director | ||
| Anthony Coles, Independent Director | ||
| Kirk Kaminsky, President Business | ||
| Kathleen McElligott, Executive Vice President CTO, CIO | ||
| Nancy Avila, Chief VP | ||
| Paul Julian, Executive Vice President, Group President | ||
| James Hinton, Director | ||
| Richard Carmona, Independent Director | ||
| Kevin Emerson, Interim Senior Vice President Chief Accounting Officer, Controller | ||
| David Lawrence, Independent Director | ||
| Tom Rodgers, Executive Vice President and Chief Strategy and Business Development Officer | ||
| Paul Smith, VP Taxes | ||
| Craig Mercer, Senior Vice President Investor Relations | ||
| Rachel Rodriguez, Vice Relations | ||
| Britt Vitalone, Chief Financial Officer, Executive Vice President | ||
| Francisco Fraga, Chief VP | ||
| Patrick Blake, Executive VP and Group Pres | ||
| Brian Tyler, President, Chief Executive Officer, Chief Operating Officer, Director | ||
| MChristine Jacobs, Independent Director | ||
| Erin Lampert, Vice President - Investor Relations |
McKesson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is McKesson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 0.0363 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 75 B | ||||
| Shares Outstanding | 131.41 M | ||||
| Shares Owned By Insiders | 0.06 % | ||||
| Shares Owned By Institutions | 88.46 % | ||||
| Number Of Shares Shorted | 1.46 M | ||||
| Price To Earning | 26.98 X | ||||
| Price To Book | 5.04 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in McKesson. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy McKesson Stock please use our How to buy in McKesson Stock guide.Note that the McKesson information on this page should be used as a complementary analysis to other McKesson's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Complementary Tools for McKesson Stock analysis
When running McKesson's price analysis, check to measure McKesson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy McKesson is operating at the current time. Most of McKesson's value examination focuses on studying past and present price action to predict the probability of McKesson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move McKesson's price. Additionally, you may evaluate how the addition of McKesson to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is McKesson's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of McKesson. If investors know McKesson will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about McKesson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.42) | Dividend Share 2.32 | Earnings Share 22.1 | Revenue Per Share 2.2 K | Quarterly Revenue Growth 0.148 |
The market value of McKesson is measured differently than its book value, which is the value of McKesson that is recorded on the company's balance sheet. Investors also form their own opinion of McKesson's value that differs from its market value or its book value, called intrinsic value, which is McKesson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because McKesson's market value can be influenced by many factors that don't directly affect McKesson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between McKesson's value and its price as these two are different measures arrived at by different means. Investors typically determine if McKesson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, McKesson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.